Amin Khalifa mostly held executive financial positions, his most recent role was CFO for Iris International.
Mr. Khalifa served eight years on the PetSmart board of directors. Previously, Mr. Khalifa was CFO and executive vice president at Apria Healthcare. He also served as Vice President – Finance and CFO of Beckman Coulter. He was CFO of Monsanto's agricultural sector and CFO of Aetna Health Plans and had a fifteen-year tenure at PepsiCo.

John Osth is an experienced and well-rounded senior executive in the medical/scientific industry. At various points in his career he has served as CEO, President, CFO, head of R&D, VP of Business Development, head of sales and marketing, and manager of diagnostics manufacturing. Of particular note, he was President of the Immunotherapy Division of Baxter Healthcare and CEO of Celula, Inc., a VC backed genomics start-up.

Dr. Vicki Clements is an accomplished executive in the biotechnology and medical device sectors. Her recent roles include Vice President of Sales and Vice President of Marketing for two early stage medical device companies. Previously, Vicki was founder and President of NanoSciences, Inc. Earlier, she was the Chief Operating Officer for Irvine Scientific. She is a contributing author to the book Marketing of High-Tech Products and Services.

Dr. Masato Mitsuhashi began his career as a pediatrician with a subspecialty in allergy/immunology. In 1985 he joined Dr. Goetzl's laboratory at UCSF as a post doc. He then joined Hitachi Chemical Research Center, advancing to the position of CSO.
As the Chief Technology Officer at NanoSomiX, he is using this expertise to translate research advances using exosomes in blood into clinically applicable laboratory developed tests.

Dr. Dennis Van Epps began his career as a Professor in the Dept of Medicine at the Univ. of New Mexico Medical School. He later joined Baxter Healthcare, advancing to VP of Research for the Immunotherapy Division. He then joined Nexell Therapeutics as VP of R&D. Prior to NanoSomiX, Dr. Van Epps was VP Research for the Medical Device Division of Allergan. He has published over 140 scientific articles and has been an inventor on over 20 patents.

Dr. Bredesen is an expert in the mechanisms of neurodegenerative diseases such as Alzheimer’s. He served as Chief Resident in Neurology at the UCSF before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA and the UCSD. He then directed the Program on Aging at the Burnham Institute before coming to the Buck Institute in 1998 as its founding President and CEO.

Edward J. Goetzl is an academic clinical immunologist and rheumatologist. After ten years on the faculty of Harvard Medical School, Dr. Goetzl came to U.C.S.F. as a Professor of Medicine and Immunology. Later, he initiated studies on human molecular mechanisms of aging. He began to conduct investigations at the National Institute on Aging and has recently published several journals on diagnostic approaches to human neurodegenerative processes.

With over 30 years of early-stage venture capital experience Randy has consistently found, financed and supported creative entrepreneurs who have grown businesses that are leaders in their fields. Randy is currently the Managing Director of Catalina Ventures.
Earlier in his career, Randy was a founder of Palomar Ventures.
The Forum for Corporate Directors honored Randy in 2010 as Director of the Year – Early Stage Companies.